Perry A Karsen is Director of Jounce Therapeutics, Inc.. Currently has a direct ownership of 0 shares of JNCE, which is worth approximately $0. The most recent transaction as insider was on May 03, 2023, when has been sold 5,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

PERRY A KARSEN Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 03 2023
SELL
Disposition due to a tender of shares in a change of control transaction
-
5,000 Reduced 100.0%
0 Common Stock

Also insider at

NTLA
Intellia Therapeutics, Inc. Healthcare
GRPH
Graphite Bio, Inc. Healthcare
PAK

Perry A Karsen

Director
Cambridge, MA

Track Institutional and Insider Activities on JNCE

Follow Jounce Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells JNCE shares.

Notify only if

Insider Trading

Get notified when an Jounce Therapeutics, Inc. insider buys or sells JNCE shares.

Notify only if

News

Receive news related to Jounce Therapeutics, Inc.

Track Activities on JNCE